{"entity":{"id":"nct07365592","kind":"trial","name":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","aka":["Neo-CD"],"tldr":"A phase 1/2 trial of fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","summary":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC is a phase 1/2, randomised interventional study registered as NCT07365592 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 138 participants, started 2026-04-09 and due to reach its primary completion in 2029-12-01. Interventions recorded: Oxaliplatin; Capecitabine; Anti-PD-1 monoclonal antibody; Sitagliptin (DPP4 inhibitor). Conditions listed: Colorectal Cancer. Primary outcome: Adverse events (AEs); Dose limiting toxicities (DLTs); Proportion of patients achieving tumor regression grade 0/1 (TRG 0/1). Colorectal eligibility wording from the registry: \"* Pathologically diagnosed colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07365592","url":"https://clinicaltrials.gov/study/NCT07365592"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["folfox","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07365592","phase":"1/2","setting":"A Phase Ib/II Study of Neoadjuvant Chemotherapy Combined With Anti-PD-1 Antibody and DPP4 Inhibitor Sitagliptin for Locally Advanced pMMR Colorectal Cancer","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","enrolled":138,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07365592/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}